Qiagen, Helix partner to advance CDx for hereditary diseases

Create PDF

The partnership will leverage the Helix Laboratory platform, which was granted the first FDA de novo class II authorization for a whole exome sequencing platform. Qiagen’s companion diagnostic offerings encompass technologies from next-generation sequencing to polymerase chain reaction and digital PCR.